Literature DB >> 7879414

Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen.

H L Davis1, M L Michel, M Mancini, M Schleef, R G Whalen.   

Abstract

Direct gene transfer by intramuscular injection of plasmid DNA encoding an antigenic protein may be used for the purpose of immunization. DNA-based immunization may be of value for basic immunological research and vaccine development. Several factors influence the uptake and expression of plasmid DNA in skeletal muscle, which in turn influence the immune response to the expressed protein. Physical barriers and other factors may impede diffusion of the DNA within the muscle tissue or its entry into the muscle fibres. Although the efficiency of gene transfer in normal mouse muscle is low (< 100 fibres per injection site), a humoral response to the hepatitis B surface antigen (HBsAg) is obtained after expression of a transferred gene. Direct gene transfer is ten times more efficient in regenerating than in normal mouse muscle. DNA-based immunization in such regenerating muscles results in an earlier and stronger humoral response to HBsAg than is seen in normal mature muscle. A needleless jet injection system (Biojector) is able to deliver DNA into normal muscle in rats and rabbits such that a substantial immune response is obtained.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7879414     DOI: 10.1016/0264-410x(94)90073-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  25 in total

1.  Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.

Authors:  R Wang; J Epstein; F M Baraceros; E J Gorak; Y Charoenvit; D J Carucci; R C Hedstrom; N Rahardjo; T Gay; P Hobart; R Stout; T R Jones; T L Richie; S E Parker; D L Doolan; J Norman; S L Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

2.  Activation of the skeletal alpha-actin promoter during muscle regeneration.

Authors:  D R Marsh; J A Carson; L N Stewart; F W Booth
Journal:  J Muscle Res Cell Motil       Date:  1998-11       Impact factor: 2.698

3.  DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines.

Authors:  H L Davis; M J McCluskie; J L Gerin; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

4.  DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state.

Authors:  M Mancini; M Hadchouel; H L Davis; R G Whalen; P Tiollais; M L Michel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

5.  Genetic vaccination against malaria infection by intradermal and epidermal injections of a plasmid containing the gene encoding the Plasmodium berghei circumsporozoite protein.

Authors:  R Weiss; W W Leitner; S Scheiblhofer; D Chen; A Bernhaupt; S Mostböck; J Thalhamer; J A Lyon
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 6.  Genetic vaccines: strategies for optimization.

Authors:  G Gregoriadis
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

Review 7.  Genetic vaccines--a revolution in vaccinology?

Authors:  Z Q Xiang; S Pasquini; Z He; H Deng; Y Wang; M A Blaszczyk-Thurin; H C Ertl
Journal:  Springer Semin Immunopathol       Date:  1997

Review 8.  Genetic vaccination against tuberculosis.

Authors:  D B Lowrie; C L Silva; R E Tascon
Journal:  Springer Semin Immunopathol       Date:  1997

9.  Stable and long-lasting immune response in horses after DNA vaccination against equine arteritis virus.

Authors:  M Giese; U Bahr; N J Jakob; R Kehm; M Handermann; H Müller; T H Vahlenkamp; C Spiess; T H Schneider; G Schusse; G Darai
Journal:  Virus Genes       Date:  2002-10       Impact factor: 2.332

10.  Immunisation with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus.

Authors:  R J Phillpotts; K Venugopal; T Brooks
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.